A Podcast with Otis Brawley

Article

Recently I reviewed Otis Brawley's provocative book, How We Do Harm: A Doctor Breaks Rank About Being Sick in America. In the book, Brawley, the chief medical and scientific officer of the American Cancer Society (and a member of CURE's scientific advisory board), takes issue with how the American healthcare system often provides far too much or far too little healthcare, and reveals how neither is good when it comes to treating cancer. You can read the full review here. Last Sunday, Joe and Terry Graedon of The People's Pharmacy interviewed Brawley about his book as well as his thoughts on various cancer screening methods, including the PSA test for prostate cancer and the spiral CT scans for lung cancer. The often skeptical Brawley digs deeper into these tests and provides context for the statistics, as well as his own advice on what patients should do when confronted with what has become a very confusing topic. To be sure, this hour-long podcast entitled The Underbelly of Healthcare (available here) is worth a listen and is free for four weeks following its August 25 release. After that, a digital download is available for $2.99.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content